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Objectives. This study sought to prospectively observe the 
morphologic and clinical natural history of severe atherosclerotic 
disease of the thoracic aorta as defined by transesophageal 
echocardiography. 
Background. Atherosclerosis of the thoracic aorta has been 
shown to be highly associated with risk for embolic events in 
transesophageal studies, but the natural history of the disease 
under clinical conditions has not been reported. 
Methods. During a 20-month period, 191 of 264 patients 
undergoing transesophageal chocardiography ad adequate vi- 
sualization of the aorta to allow atherosclerotic severity to be 
graded as follows: grade I = normal (44 patients); grade H = 
intimal thickening (52 patients); grade III = atheroma <5 mm (62 
patients); grade IV = atheroma >5 mm (19 patients); grade V = 
mobile lesion (14 patients). All available patients with grades IV 
(8 patients) and V (10 patients) disease as well as a subgroup of 
12 patients with grade III disease had follow-up transesophageal 
echocardiographic studies (mean [-+SD] 11.7 _+ 0.9 months, 
range 6 to 22). 
Results. Of 30 patients undergoing follow-up transesophageal 
echocardiographic studies, 20 (66%) had no change in atheroscle- 
rotic severity grade. Of the remaining 10 patients, atherosclerotic 
severity progressed one grade in 7 and decreased in 3 with 
resolved mobile lesions. Of 18 patients with grade IV or V disease 
of the aorta who underwent a follow-up study, 11 (61%) demon- 
strated formation of new mobile lesions. Of 10 patients with grade 
V disease on initial study who underwent follow-up study, 7 (70%) 
demonstrated resolution of a specific previously documented 
mobile lesion. However, seven patients (70%) with grade V disease 
also demonstrated development of a new mobile lesion. Of 33 
patients with grade IV or V disease, 8 (24%) died during the study 
period, and 1 (3%) had a clinical embolic event. 
Conclusions. The presence of severe atherosclerotic disease of 
the thoracic aorta as defined by transesophageal chocardiogra- 
phy is associated with a high mortality rate. Although the mor- 
phologic natural history of the disease process itself is marked by 
stability over a 1-year period, individual esion morphology is
dynamic, with formation and resolution of mobile components 
occurring frequently over the same period. The dynamic nature of 
individual lesion morphology potentially enhances the possibility 
of developing a successful therapeutic strategy. 
(J Am Coil Cardiol 1996;27:95-101) 
The natural history of the atherosclerotic process is one of a 
slowly progressive inflammatory disease of the arterial vascu- 
lature, with plaque formation taking place over several decades 
(1,2). The slow but inexorable progression is interspersed with 
episodes of plaque rupture that may lead to changes in lesion 
morphology and associated clinical events (3). This well ac- 
cepted understanding of the atherosclerotic process is based 
on autopsy series as well as clinical studies of the disease 
(4-6). More recent studies of the natural history of the 
atherosclerotic process have focused on the ability to intervene 
in the anatomic and clinical progression ofthe disease through 
behavior modification or drug therapy (7-11). 
In recent years, ultrasound technology has made possible 
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high resolution imaging of atherosclerosis in the arterial 
vasculature (12-14). With the ability to assess lesion size (15), 
composition (16) and dynamic effect on flow (17), ultrasound 
technology offers new insights into an old disease. The advent 
of transesophageal chocardiography brought with it the abil- 
ity to image the atherosclerotic process in the thoracic aorta, 
yielding images of the aortic initima and lumen, including 
atherosclerotic plaque morphology and, when present, plaque 
mobility. The majority of transesophageal chocardiographic 
studies of thoracic aortic atherosclerosis have focused on the 
clinical relevance of the disease (12,18-24). Severe atheroma- 
tous disease of the thoracic aorta has recently been associated 
with a markedly increased risk of embolic events (18- 
22,24,25). In a case-control prospective study by Amarenco et 
al. (18), a ninefold increase in risk for ischemic stroke was 
associated with transesophageal chocardiographic identifica- 
tion of atherosclerotic plaques ->4 mm in the ascending aorta 
and proximal arch. That and previous tudies (18-22,24,25) as
well as autopsy data (26) clearly demonstrate he association 
between severe aortic atherosclerosis and embolic events, 
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particularly ischemic stroke. Transesophageal echocardio- 
graphically detected atherosclerosis of the aorta has also been 
found to be a marker for obstructive coronary artery disease 
(12,23), carotid artery disease (12) and peripheral vascular 
disease (12). Thus, transesophageal echocardiography as 
ushered in a new era in the study of atherosclerotic disease of 
the aorta and its clinical sequelae. 
Despite many transesophageal chocardiographic studies 
demonstrating the clinical importance of protruding aortic 
atherosclerosic plaques, there have been only case reports 
offering insights into the natural history or progression ofthese 
lesions (27-30). Transesophageal chocardiography is a safe 
(31,32), semiinvasive procedure that makes possible longitudi- 
nal studies of the aorta. Thus, transesophageal chocardiogra- 
play lends itself to use as a means of observing the progression 
of thoracic aortic atherosclerosis. In the future it may provide 
a means of monitoring efficacy of therapies for atherosclerosis. 
An understanding of the natural history and pathology of the 
disease process is important o make possible a rational 
approach to therapy. 
Because of the virtual absence of longitudinal studies of the 
natural history of severe atheromatous di ease of the aorta, we 
undertook a prospective echocardiographic and clinical study 
of patients with known severe atherosclerosis of the thoracic 
aorta. The goals of the present study were to determine the 
morphologic progression of protruding aortic atheromatous 
disease and to prospectively study the clinical course of the 
study cohort. 
Grade I Grade IV 
Grade II Grade V 
Methods 
Study group. Between September 1992 and July 1994, 264 
patients underwent transesophageal chocardiographic study 
at our institution. In 73 of these patients, the aorta was not 
completely imaged from the aortic root to the level of the 
diaphragm. Therefore, only 191 patients with adequate imag- 
ing of the entire aorta were eligible for inclusion in the study. 
The aortic images of all transesophageal chocardiographic 
studies during that time period were reviewed, and each 
patient's aorta was graded according to the severity of athero- 
sclerosis. The grading system used was a modification of that 
used by Ribakov et al. (24). Briefly, grade I = no disease or 
intimal thickening (44 patients); grade H = intimal thickening 
(52 patients); grade III = atheroma <5 mm (62 patients); grade 
IV = atheroma ->5 mm (19 patients); grade V -- any mobile 
atheroma (14 patients) (Fig. 1). Our goal was to perform 
follow-up transesophageal echocardiographic studies in all 
patients with severe atherosclerotic disease of the thoracic 
aorta at a minimal time interval of 6 months between studies. 
All patients with grade IV or V atherosclerosis of the 
thoracic aorta comprised the main study group. A second 
group of patients with grade III disease was chosen to repre- 
sent more moderate disease. Any patient in these two groups 
who had two transesophageal chocardiographic studies of the 
aorta >6 months apart in time was automatically enrolled. The 
remaining patients were contacted by telephone or letter and 
Grade I l l  
Figure l. Grading system for severity of atherosclerosis in the thoracic 
aorta. Grade I = normal or minimal intimal thickening; Grade II : 
extensive intimal thickening; Grade III = atheroma <5 mm; 
Grade IV = atheroma ->5 mm; Grade V = mobile lesion. 
asked to participate in the study. A patient was classified as 
unavailable if there was a contraindication for the study, was 
incapacitated or in a long-term care facility, had moved from 
the local area or could not be contacted. 
The study protocol was approved by the institutional review 
board of the Emory University School of Medicine. All pa- 
tients gave written informed consent before each study. There 
were no adverse outcomes or complications. 
Transesophageal echocardiographic examination. All 
studies were performed with a Hewlett-Packard Sonos 1500 
ultrasound system and a 5-MHz biplane or 5-MHz multiplane 
transducer. The patient fasted the night before the study. For 
the procedure, the patient was placed in the left lateral 
decubitus position. The oropharynx was anesthetized with 10% 
topical lidocaine spray, and the patient was given light sedation 
with midazolam. The esophagus was intubated, and a cardiac 
examination was performed. After examination, the transducer 
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was rotated to image the aorta in the horizontal axis. The 
transducer was advanced until adequate images of the aorta 
could no longer be obtained. The transducer was then slowly 
withdrawn, obtaining both horizontal and vertical axis images 
of the descending and arch portions of the aorta. All studies 
were recorded on VHS tape. 
Transesophageal echocardiographie analysis. The aortic 
images were reviewed by three experienced echocardio- 
graphers (D.H.M., J.J.V., W.R.T.) in blinded manner. The 
aorta was graded from I to V, according to severity of 
atherosclerosis, as described earlier. Atheroma size was as- 
sessed only in the horizontal axis. In the event of disagreement, 
the majority view was taken. Interobserver concordance was 
92.5% and intraobserver concordance 95%. All studies with 
mobile lesions were reviewed with simultaneous display of the 
previous tudy to determine visually whether the lesion ob- 
served was the same mobile lesion previously documented ora 
new lesion. 
Clinical data. Clinical data were obtained principally by 
chart review of each patient. In addition, a history was 
obtained from each patient who returned for repeat trans- 
esophageal echocardiographic studies. Cardiac risk factors in 
the present study included hypertension, smoking history, 
diabetes mellitus and hypercholesterolemia. Hypertension was 
determined to be present if the patient's chart included a 
diagnosis of hypertension requiring pharmacologic therapy for 
blood pressure control. A history of smoking was defined as 
->20 pack-years. Hypercholesterolemia wasconsidered present 
if the fasting total cholesterol level was >200 mg/dl. 
Information regarding associated comorbidities, including 
coronary artery disease, ischemic neurologic events, peripheral 
embolic events, peripheral vascular disease and end-stage 
renal disease, was collected. A diagnosis of coronary artery. 
disease was assigned in the presence of documented myocar- 
dial infarction, pathologic Q waves on the electrocardiogram 
or >50% diameter coronary artery obstructions on angiogra- 
phy. An ischemic neurologic event was deemed to have occurred 
if the diagnosis was present on the chart, with documentation 
of nonhemorrhagic etiology and if appropriate associated 
physical findings were present. Peripheral embolic events in- 
cluded retinal artery embolism, amaurosis fugax and any 
documented embolic event in the extremities. End-stage renal 
disease was defined as the need for long-term dialysis. 
Statistical evaluation. Results are presented as mean 
value _+ SEM. Mantel-Haenzel chi-square analysis was used 
for comparisons of clinical characteristics. All other compari- 
sons were made using one-way analysis of variance. 
Results  
Study group. During the period October 1992 through 
June 1994, 191 patients had transesophageal echocardio- 
graphic studies with sufficient visualization of the aorta to allow 
assignment of atherosclerotic severity grade. Of these 191 
patients, 14 were assigned grade V (7%) and 19 grade IV 
(10%). The predominant site of disease was in the descending 
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Figure 2. Patient-specific change in atherosclerotic severity grade 
from initial to follow-up study. 
thoracic aorta. The indications for initial study in patients with 
severe disease were history of embolic event (11 patients 
[33%]); evaluation of valvular disease (5 patients [15%]), left 
ventricular function (4 patients [12%]) and right atrial mass (2 
patients [6%]); and to rule out endocarditis (5patients [15%]), 
left atrial thrombus before cardioversion (2 patients [6%]), 
aortic dissection (2 patients [6%]), pulmonary embolus (1 
patient [3%]) and atrial septal defect (1 patient [3%]). Of 14 
patients with grade V disease of the aorta, 10 returned for 
repeat study (71%), 1 died (7%), and 3 were unavailable (21%) 
(1 was in a long-term care facility, 2 developed medical 
contraindications to transesophageal chocardiography). Of 19 
patients with grade IV disease of the aorta, 8 patients returned 
for follow-up study (42%), 7 died (37%), and 4 were unavail- 
able (21%) (2 in long-term care facilities, 1 relocated, I lost to 
follow-up). Twelve patients with grade III atherosclerotic 
disease of the aorta underwent repeat ransesophageal cho- 
cardiographic studies. These patients were randomly selected 
to represent the larger group of patients with moderate disease 
in our cohort. These repeat studies were not performed for 
clinical indications (average time to repeat study 11.7 _+ 0.9 
months, range 6 to 22). 
Morphology/progression data. The progression i grade of 
aortic atheromatous disease in our patients during the study 
period is presented in Figure 2. Of 12 patients with grade Ill 
atherosclerotic disease of the aorta on initial study, 9 still had 
grade Ill disease on repeat study (75%), but 3 developed grade 
IV disease (25%). Of eight patients with grade IV aortic 
atherosclerosis, four had developed mobile components of 
aortic plaque during the interim period (50%), but the other 
four had no change in grade (50%). Seven (70%) of 10 study 
patients with grade V aortic disease on initial transesophageal 
echocardiographic study had mobile components of athero- 
sclerotic plaque on repeat study. However, the other three 
patients (30%) had no evidence of the previously present 
mobile plaque on repeat study. Thus, the atherosclerotic 
disease process, as measured by atherosclerotic severity grade, 
remained stable over the study period in 20 (66%) of 30 
patients undergoing follow-up examination. 
With the use of landmarks, it was also possible to document 
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Figure 4. Occurrence ofnew mobile lesions in patients with preexist- 
ing atheromatous di ease of the thoracic aorta. Open bars = total 
number of patients; olid bars = number of patients with new mobile 
lesions. 
Figure 3. Changes in atherosclerotic mobile lesion morphology with 
time. Top, Follow-up image 10 months after the initial image reveals 
the presence of the same lesion with little change in morphology 
(arrows). Middle, Follow-up image reveals resolution of a mobile 
lesion (arrow) present on initial study 6 months earlier. Bottom, 
Follow-up image demonstrates hedevelopment of a long, thin mobile 
lesion (arrow) not present on initial study 11 months before. 
changes in the morphology ofa lesion over time, including the 
formation, resolution and persistence of mobile lesions (Fig. 
3). Of the patients with persistent grade V disease, the initial 
mobile lesion was not visualized in four patients (57%). 
However, these patients had clearly developed additional 
mobile lesions at a different anatomic location. The other three 
patients (43%) had what appeared to be the same mobile 
plaque imaged on initial study and new mobile lesions on 
repeat study. Thus, all seven patients with persistent grade V 
disease demonstrated vidence of new mobile lesion formation 
(Fig. 4). 
Mobile lesions of the thoracic aorta were observed to vary 
in size and shape. In reviewing the characteristics of all the 
mobile lesions (grade V), we found that each mobile lesion 
could be subclassified into one of three fairly distinct morpho- 
logic categories: 1) a discreet 1- to 2-mm mobile lesion; 2) a 
long, slender lesion that moved freely in the pulsatile flow of 
the aorta; and 3) (most common) a large mass that rocked in 
place with aortic blood flow. All three lesion types were found 
to develop and resolve during the study period. Whether the 
difference in morphology was associated with a difference in 
clinical course could not be determined. 
Clinical data. Clinical data with regard to prevalence of 
risk factors, other manifestations of atherosclerosis and anti- 
thrombotic therapy are presented in Table 1. The prevalence 
of all four major risk factors for atherosclerosis was relatively 
high in our study cohort. Of the 19 patients with grade IV 
disease on initial study, only 2 had no clinical manifestations of 
atherosclerosis (11%) (i.e., coronary artery disease, peripheral 
vascular disease, neurovascular disease, embolic events). 
Three patients (21%) with grade V disease on initial study 
manifested no other clinical forms of severe atherosclerosis. Of 
the 33 patients with grade IV or V disease on initial study, 8 
died during the follow-up period (24%) (Fig. 5). The precise 
cause of death was available for one patient only (sepsis). 
Only two clinical embolic events occurred during the 
follow-up period. One patient with grade III disease on initial 
and follow-up study had a stroke during the interim period. 
The second patient had grade IV disease on initial study that 
progressed to grade V disease on repeat study. This patient 
had a stroke after coronary bypass surgery. No patient with 
grade V disease on initial study had a clinical embolic event 
during the follow-up period. However, five of these patients 
Figure 5. Survival curve for patients with severe atheromatous di ease 
(grade IV or V) on transesophageal echocardiography (TEE). 
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Table 1. Baseline Clinical Characteristics byAtherosclerotic 
Severity Grade 
Grade IIl Grade IV Grade V 
(n - 12) (n = 19) (n = 14) p Value 
Mean (~-SD) age (yr) 64 _+ 4.1 70 _+ 1.1 68 + 1.5 0.21 
Hypertension 58 79 86 0.24 
Tobacco abuse 100 84 86 0.36 
Diabetes mellitus 25 47 57 0.24 
Hypereholesterolemia 67 79 86 0.50 
Coronau, arte~ disease 75 58 79 0.39 
StrokeFFIA/embolic event 33 52 36 0.80 
Peripheral vascular disease 42 58 43 0.59 
End-stage renal disease 8 5 21 0.55 
Aspirin 75 42 57 0.20 
Warfarin 8 21 21 0.61 
Unless otherwise indicated, data presented are percent of patients. TIA - 
transient ischemic attack. 
(36%) had ischemic neurologic events preceding the initial 
study. 
Discussion 
We found that in a defined cohort of patients with severe 
disease (grades IV and V), a contrast existed between the 
stability of the disease process itself and the dynamic and 
progressive nature of individual esion morphology. The over- 
all atherosclerotic grade did not change in the majority of 
patients (61%) throughout he follow-up period, reflecting 
relative stability in the disease process. Conversely, individual 
lesion morphology was dynamic, with 62% of patients devel- 
oping new mobile lesions and 70% demonstrating resolution of 
previously identified mobile lesions. The poor prognosis asso- 
ciated with the most advanced stages of this disease process 
clearly dictates the need for a form of therapeutic intervention. 
The finding that mobile lesions are a manifestation of a 
markedly dynamic process ignificantly enhances the possibility 
for developing a successful therapeutic strategy. 
Severe atherosclerosis ( .e., grade IV or V) of the thoracic 
aorta is a common finding on transesophageal chocardiogra- 
phy. Prevalence rates for the disease on routine transesopha- 
geal echocardiographic studies range from 7% (21) to 17% 
(this study). The finding of mobile lesions on routine trans- 
esophageal echocardiographic studies ranges from 2% (21) to 
7% (found in this study). Recent studies (12,18-25) have 
demonstrated the clinical importance of severe atherosclerosis 
as an independent risk factor for embolic events and associated 
atherosclerotic disease. The presence of a mobile plaque 
appears to confer a particularly high risk for embolism (21). 
Aside from risk factor modification, there has been no consen- 
sus on therapeutic options for the disease. To make rational 
decisions regarding management, i  will be necessary to have 
an understanding of the pathology and natural history of 
thoracic aortic atherosclerosis. To our knowledge, this study is 
the first effort toward describing the natural history of severe 
atherosclerosis of the thoracic aorta as defined by transesoph- 
ageal echocardiography. 
Several case reports have documented changes in mobile 
lesion morphology over time. Two case studies by Dee et al. 
(27) demonstrated resolution of mobile components ofathero- 
sclerotic plaque on repeat ransesophageal chocardiography 
after 3 to 4 weeks of systemic anticoagulation. Mitchell et al. 
(28) reported acase in which a mobile lesion in the descending 
aorta was unchanged on repeat ransesophageal chocardiog- 
raphy after 2 months without systemic anticoagulation. Aldrich 
et al. (29) reported that repeat transesophageal chocardio- 
graphic studies after a clinical embolic event revealed the 
absence of a large mobile mass that was present at the distal 
aortic arch 3 days earlier (29). Finally, Hausmann et al. (30) 
reported resolution of a large pedunculated distal aortic arch 
lesion after thrombolytic therapy. The present study expands 
on previous experience by systematically observing changes in 
severe atherosclerotic lesion morphology over time in a large 
group of patients. 
Progression. The natural history of atherosclerosis in the 
coronary arteries (33), the carotid arteries (34-36), the renal 
arteries (37,38) and the peripheral vasculature (39) has previ- 
ously been investigated. These and other studies, including 
autopsy data (4,5), are the basis for our current understanding 
of the atherosclerotic process. Atherosclerosis is a slow inflam- 
matory process, leading eventually to plaque formation over 
many years. This slow growth is interspersed with episodes of 
plaque rupture that may lead to changes in lesion morphology 
and clinical activity. In our study of atherosclerosis of the 
thoracic aorta, 66% of patients howed no change in grade of 
atherosclerotic severity over the follow-up period of -1  year. 
The natural history of the atherosclerotic process in the aorta 
would appear to be one of slow growth with disease stability, as 
would be expected on the basis of our previous understanding 
of the disease. 
In contrast to the stable nature of the disease process itself 
is the apparent instability in morphology of individual athero- 
sclerotic lesions of the thoracic aorta. Atherosclerotic grade 
changed in 10 patients (33%), seven of whom either developed 
or resolved specific mobile lesions. Although no patients with 
grade III disease on initial study developed mobile lesions, 
50% of patients with grade IV disease on initial study devel- 
oped mobile lesions during the study period. Additionally, all 
patients with grade V disease who remained in grade V on 
follow-up study had evidence of at least one new mobile lesion. 
Thus, 11 (61%) of 18 patients with grade IV or V disease on 
initial study demonstrated formation of new mobile lesions 
over the -1-year follow-up period. The formation of mobile 
lesions, presumably the result of plaque rupture, occurs fre- 
quently in patients with more severe atherosclerotic disease. 
In addition to the frequent formation of mobile lesions, 
many patients also demonstrate r solution of such lesions over 
time. Of the 10 patients with grade V disease on initial study, 
3 had no visible mobile plaque on follow-up study. In addition, 
in four of the seven patients whose disease remained grade V 
on repeat ransesophageal chocardiography t e mobile lesion 
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seen on initial study appeared to have resolved. Thus, 7 (70%) 
of 10 patients with grade V disease on initial study demon- 
strated resolution of a mobile lesion. Whether the absence of 
a previously mobile lesion represents embolization or healing 
remains unknown. None of the seven patients with lesions that 
resolved had clinically evident embolic events during the study 
period. 
There are clinical implications for the finding that severe 
atheromatous disease of the thoracic aorta may represent a
dynamic process, with formation and resolution of mobile 
plaque components. Karalis et al. (21) demonstrated that the 
incidence of embolic events was higher in the presence of 
mobile debris than with layered isease (73% vs. 12%). It is 
possible that plaque rupture with the formation of a mobile 
atheroma precedes the clinical embolic event. Thus, therapy 
should be aimed at preventing plaque rupture, decreasing the 
embolic potential of the mobile lesion or promoting healing of 
the mobile component. 
Morphology. Our observation that mobile components of
plaque may take several forms has not been confirmed in 
published reports. We believe it likely that mobile lesions 
represent portions of the fibrous cap of an atheroma that has 
ruptured. Surgical and autopsy specimens of embolic material 
in patients with severe aortic atherosclerosis have revealed 
thrombus (12,29), atheromatous material (22,40) and choles- 
terol crystals (25,41). The exact composition of transesopha- 
geal echocardiographically identified mobile lesions has not 
been defined. Pathologic study of these mobile lesions is 
important for implications regarding the use of anticoagulant 
agents in this disease. Whether the various morphologies of 
mobile lesions observed represent potential differences in 
composition or clinical course is unclear. 
Clinical implications. The presence of grade IV or V 
atherosclerosis of the thoracic aorta appears to confer a poor 
prognosis. Of the 33 patients with grade IV or V disease in our 
study, 8 died (24%) during the 1-year follow-up period. The 
lack of information regarding the precise cause of death in our 
study limits the interpretation f these data. However, asimilar 
mortality rate of 27% over a 6-month period among patients 
with aortic lesions >5 mm was reported by Hilton et al. (41). 
In another prospective study, Tunick et al. (19) reported a 21% 
mortality rate among 42 patients with protruding atheroma 
followed over an average of 14 months. 
Surprisingly, only 1 patient (3%) among the 33 in our study 
with grade IV or V disease had a documented mbolic event (a 
perioperative stroke) during the follow-up period. This finding 
is in contrast to a 13% embolic event rate in the study by Hilton 
et al. (41) and a 33% embolic event rate in that by Tunick et al. 
(19). This discrepancy may be due to different data collection 
methods, small sample size or patient selection (i.e., preva- 
lence of disease involving the descending thoracic aorta). 
Although our study did not address the issue of antiplatelet 
or antithrombotic agents as therapy for severe aortic athero- 
sclerosis, the anecdotal data is intriguing. The use of antiplate- 
let or antithrombotic agents as therapy for embolic events 
thought o be related to the aorta is controversial. In the 
present study, aspirin use did not protect against he develop- 
ment of mobile plaques. Nine (82%) of 11 patients with grade 
V lesions on repeat ransesophageal echocardiography were 
taking aspirin during the study period. This finding does not 
preclude the possibility that aspirin may protect against clinical 
embolic events. Aspirin does prevent clinical events related to 
atherosclerosis of smaller arteries, such as the coronary and 
carotid vessels (43). However, it is not clear that the patho- 
genesis of embolism in these vessels is the same as that in the 
aorta. In fact, neither of the small prospective studies by Hilton 
et al. (41) or Tunick et al. (19) showed a benefit for aspirin or 
warfarin therapy in reducing morbidity or mortality in patients 
with severe atherosclerotic disease of the aorta. Aside from the 
antiplatelet ffect, there is evidence for an antiatherogenic effect 
of aspirin in the carotid artery (10). The effectiveness of aspirin 
therapy in the treatment of severe atherosclerosis of the aorta 
remains to be more clearly defined in a large prospective study. 
The effect of warfarin on the formation and persistence of 
mobile lesions is also unclear. Dee et al. (27) reported two 
cases in which mobile lesions resolved on warfarin therapy. In 
our study, two patients had mobile lesions on transesophageal 
echocardiography despite use of warfarin for an extended 
period before the study. We have since had a third patient with 
multiple mobile lesions despite prolonged warfarin therapy. 
However, one patient with warfarin therapy and a mobile lesion 
on initial study showed resolution of the lesion on follow-up. Also, 
of the four patients with grade IV disease that remained in grade 
IV on repeat ransesophageal chocardiography, twowere taking 
warfarin. As a consequence of studies implicating warfarin as a 
possible precipitant of cholesterol embolization (44-46), its use 
in peripheral embolic syndromes i  not generally recommended. 
The number of patients in our study is too small to draw firm 
conclusions about he effect of warfarin on the natural history of 
atherosclerotic lesions or their clinical course. 
Study limitations. Our study has several potential limita- 
tions. Our study group was small, and the patients able to return 
for follow-up represent a selected subgroup. This limitation is 
unlikely to affect he morphologic or progression data but may 
have an impact on the ability to document and draw conclusions 
regarding nonmortal clinical events. The grading system used in 
our study is a measure of disease severity based on the most 
severe lesion noted. A severity index correlates well with but does 
not always reflect the extent of disease. We did attempt to 
measure xtent of disease by labeling the process focal or diffuse 
in each aorta. Diffuse disease was defined as greater than two- 
thirds intimal involvement with atherosclerosis. Thirty-one (94%) 
of 33 patients with grade IV or V disease were classified as having 
diffuse disease. Hence, in our study, disease severity correlated 
well with extent of disease. 
Conclusions. Consistent with our understanding of the 
pathogenesis of the process, our study reveals that the natural 
history of atherosclerosis of the thoracic aorta appears to be 
one of stability, with the majority of patients demonstrating o
change in the severity of the disease process over a 1-year period. 
In contrast, he morphology of individual severe atherosclerotic 
lesions represents a dynamic process, with the formation and 
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resolution of mobile components of plaque an apparently fre- 
quent occurrence. The relation of this finding to clinical events is 
suggested by the increased prevalence of mobile lesions on 
transesophageal echocardiography after embolic events. Thus, 
therapy for patients who have embolic events associated with 
severe thoracic atherosclerosis hould focus on preventing the 
evolution of mobile lesions, protecting against he embolic poten- 
tial of these lesions and encouraging the healing of these lesions. 
A large-scale prospective study of the clinical and morphologic 
natural history of the disease, with a therapeutic arm of anti- 
thrombotic or lipid-lowering therapy, is needed. 
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